Adaptive Biotechnologies Corp vs Alexandria Real Estate Equities Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Alexandria Real Estate Equities Inc trades at $48.5 (market cap $8.28B). The key difference: Alexandria Real Estate Equities Inc is far larger — about 2× Adaptive Biotechnologies Corp's market cap, and Alexandria Real Estate Equities Inc pays a 5.99% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ARE | |
|---|---|---|
Market Cap | $4.04B | $8.28B |
Sector | Health | Real Estate |
52-Week High | $25.45 | $87.45 |
52-Week Low | $12.30 | $40.41 |
Enterprise Value | $4.10B | $20.98B |
Dividend Yield | — | 5.99% |
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →